Company intelligence / Profile preview

Midori Capital

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Midori Bio is a biotechnology company specializing in microbiome modulation through a proprietary glycan-based platform. Founded by Flagship Pioneering in 2011, the company develops tailored carbohydrates designed to bypass the upper digestive tract and selectively activate beneficial microbes in the gut. Midori's technology has been applied to improve animal health and nutrition, with potential applications in human therapeutics and sustainability. The company was acquired by Ginkgo Bioworks in July 2022 to enhance Ginkgo's capabilities in microbiome engineering and cell programming.

Therapeutic areas: OtherGastroenterologyMetabolic Disorders
Modalities: GlycansComplex carbohydratesMicrobiome modulators
Industry: Biotech

Partnerships

Ginkgo Bioworks

Beyond the preview

Go deeper on Midori Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Midori Capital.

Explore the full profile